FDG-PET/CT Scan Assessment of Response 12 weeks Post Radical Radiotherapy in Oropharynx Head and Neck Cancer: The Impact of p16 Status

The epidemiology of oropharyngeal cancer is evolving. Previously, this disease was frequently observed in patients with substantial tobacco and alcohol use[1]. More recently, human papillomavirus (HPV) related oropharyngeal cancer is increasing in incidence, particularly in young and non-smoking patients.[2,3]. The prevalence of HPV related oropharynx cancer has increased from 40% of all cases in Radiation Therapy Oncology Group (RTOG) 9003 to 68% on RTOG 0129 and 73% on RTOG 0522[4,5].p16 immunohistochemistry is a reliable surrogate for determining HPV status[6].

Source: Radiotherapy and Oncology - March 31, 2020 Category: Radiology Authors: Ryan Urban, Tassia Godoy, Robert Olson, Jonn Wu, Eric Berthelet, Eric Tran, Kimberly DeVries, Don Wilson, Sarah Hamilton Tags: Original Article Source Type: research